CDT Equity Inc.

What they do

CDT Equity identifies clinical-stage compounds deprioritized by larger pharmaceutical companies, particularly those with supporting Phase I safety data, and seeks to improve their properties through co-crystallization and solid-form technologies at its Cambridge facilities. It also partners with Sarborg Limited to apply AI-powered disease-signature analysis to identify new therapeutic uses and combinations. The company operates an asset-agnostic model and does not run early- or late-stage clinical trials, instead pursuing licensing and commercialization partnerships after pre-clinical in vitro and in vivo work. Its named clinical assets are AZD1656, a glucokinase activator, and AZD5904, a myeloperoxidase inhibitor.

Revenue drivers

• Licensing and partnership deals — The stated exit is third-party license agreements following successful pre-clinical trials; no such deal has been described as generating revenue, and the company says it does not expect significant revenue until a first clinical asset is adequately developed.
• Clinical-stage asset pipeline — Pipeline candidates target autoimmune disorders, idiopathic male infertility, oncology, dermatology, rare disease and animal health; these remain in development and have not received FDA or other regulatory approval.
• Solid-form intellectual property — The IP portfolio consists of pending international patent applications describing a solid-form compound including the AZD1656 cocrystal; the strategy is to extend patent life by up to 20 years and license the resulting positions.
• AI-guided repositioning — The Sarborg collaboration applies proprietary algorithms across more than 3,000 disease signatures and has informed two new combination patent filings; the company describes this as supporting future licensing rather than current revenue.

Recent performance

The company reported no meaningful revenue and continues to post significant losses. Net losses were $39.2 million in 2025 and $17.8 million in 2024, with an accumulated deficit of $68.3 million as of December 31, 2025. Operating cash flow was negative $15.6 million in 2025, versus negative $9.7 million in 2024. At June 30, 2026, total assets were $126.7 million, total liabilities $23.6 million, shareholder equity $103.1 million, and cash and equivalents only $747,000, indicating a very thin cash position relative to total assets.

Strategy

Management's stated direction is to acquire or in-license deprioritized clinical-stage compounds, improve them with solid-form and co-crystallization chemistry, and use Sarborg's AI signature analysis to find new indications and combinations. The company says it deliberately avoids the cost of early and late-stage clinical trials, aiming instead for high-leverage development work followed by licensing or partnership exits. It has filed two new combination patents informed by Sarborg insights and has initiated pre-clinical in-vitro models for new indications. Management has also stated it continues to evaluate artificial intelligence and cybernetics approaches to drug re-purposing and asset selection. No revenue-generating transaction has been described in the filings provided.

Risks

• No revenue and recurring losses — CDT Equity has never generated significant revenue and reported net losses of $39.2 million in 2025 with a $68.3 million accumulated deficit.
• Thin cash against obligations — Cash and equivalents were only $747,000 at June 30, 2026, against $23.6 million in total liabilities, implying a near-term need for additional financing.
• Dependence on two lead assets — The business depends on successful development, approval and commercialization or partnering of AZD1656 and AZD5904, neither of which has been approved by the FDA or any other regulatory body.
• Related-party AI dependence — The AI collaboration is with Sarborg Limited, a related party because CEO Dr. Andrew Regan sits on Sarborg's board and director Chele Chiavacci Farley is a Sarborg shareholder.

Outlook

Management says it will continue pre-clinical in vitro and in vivo studies guided by AI insights and pursue third-party license deals for further development, FDA approval and commercialization. It states that it expects operating losses and negative cash flow for the foreseeable future and does not expect significant revenues until a first clinical asset is successfully developed. The company acknowledges it may need debt and/or equity financing to meet future capital requirements, and that terms may not be favorable. Filings also flag the risk of maintaining its Nasdaq listing.